跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
李 懿宬
副教授
醫學系內科學科
電子郵件
hand1001
nycu.edu
tw
h-index
h10-index
h5-index
1081
引文
18
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
861
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
689
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2010
2025
每年研究成果
概覽
指紋
網路
研究成果
(52)
類似的個人檔案
(6)
指紋
查看啟用 I-Cheng Lee 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Hepatocellular Carcinoma
54%
Overall Survival
36%
Hepatocellular Carcinoma Patients
36%
Hazard Ratio
36%
Chronic Hepatitis B
31%
Unresectable Hepatocellular Carcinoma
28%
Chronic Hepatitis B Patients
27%
Transarterial Chemoembolization
26%
HBV-related Hepatocellular Carcinoma
23%
Hepatitis B e Antigen (HBeAg)
23%
Immune Checkpoint Inhibitors
20%
Hepatitis B Surface Antigen (HBsAg)
18%
Multivariate Analysis
17%
HBeAg-negative Chronic Hepatitis B
17%
Immune Checkpoint Inhibitor Treatment
17%
Hepatocellular Carcinoma Recurrence
17%
Sorafenib
16%
Taiwan
16%
Nucleos(t)ide Analogues
15%
Intermediate-stage Hepatocellular Carcinoma
15%
Risk Factors
14%
Hepatitis B
14%
Microvascular Invasion
13%
Chemotherapy
12%
Alpha-fetoprotein
12%
Sustained Virological Response
12%
Non-alcoholic Fatty Liver Disease (NAFLD)
11%
Recurrence-free Survival
11%
Direct-acting Antivirals
11%
Hepatitis B Virus Reactivation
11%
Survival Prediction
10%
Type 1 Diabetes Mellitus (T1DM)
10%
Viral Load
10%
Nivolumab
10%
Distant Recurrence
10%
Liver
10%
Objective Response
10%
Recurrence Risk
10%
Ropeginterferon alfa-2b
9%
Peginterferon Therapy
9%
Liver Histology
9%
Lenvatinib
9%
Rituximab
9%
CXCL9
9%
Asian Patients
9%
Single-center Experience
9%
Hepatitis
9%
Metallic Stent
9%
Chronic Hepatitis C
9%
Propensity Score Analysis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Hepatitis B Virus
52%
Chronic Hepatitis B
43%
Overall Survival
40%
Recurrent Disease
37%
Hepatitis B(e) Antigen
33%
Hepatitis B Antigen
25%
Immune Checkpoint Inhibitor
23%
Sorafenib
16%
Neoplasm
15%
Antivirus Agent
14%
Diseases
14%
Antiviral Therapy
13%
Hepatitis B
12%
Progression Free Survival
12%
Nivolumab
10%
Recurrence Free Survival
10%
Chemotherapy
10%
Diabetes Mellitus
9%
Antiviral Drug
9%
Lenvatinib
9%
Rituximab
9%
Chronic Hepatitis C
9%
Interferon
8%
Liver Fibrosis
7%
Malignant Neoplasm
7%
Hepatitis B Antibody
7%
Nonalcoholic Fatty Liver
7%
Prevalence
6%
Pembrolizumab
6%
Alpha Fetoprotein
6%
Entecavir
6%
Immunotherapy
5%
Gamma Interferon
5%
Adverse Event
5%
Biological Marker
5%
Regorafenib
5%
Peginterferon
5%
Chronic Kidney Failure
5%
Virus DNA
5%
Medicine and Dentistry
Hepatocellular Carcinoma
78%
Hepatitis B Virus
34%
Recurrent Disease
31%
Overall Survival
29%
Chronic Hepatitis B
28%
Transcatheter Arterial Chemoembolization
23%
Hepatitis B(e) Antigen
20%
Hazard Ratio
15%
Sorafenib
12%
Antiviral Therapy
11%
Diabetes Mellitus
9%
Nivolumab
9%
Multivariate Analysis
9%
Progression Free Survival
9%
Neoplasm
9%
Lenvatinib
9%
Nonalcoholic Fatty Liver
9%
Liver Histology
9%
Radiofrequency Ablation
9%
Bilirubin
9%
Hepatitis B Antigen
7%
Diseases
7%
Stent Placement
7%
Liver Fibrosis
6%
Pembrolizumab
6%
Recurrence Free Survival
6%
Alpha-Fetoprotein
5%
Obstruction
5%
Prevalence
5%
Liver Cancer
5%
Cancer Staging
5%
Body Mass Index
5%
Systemic Therapy
5%
